Intellia Therapeutics announced the U.K. Medicines and Healthcare products Regulatory Agency MHRA has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema HAE . The Innovation Passport is the point of entry into the U.K.’s Innovative Licensing and Access Pathway ILAP , which is designed to accelerate time to market and facilitate patient access to innovative medicines."With the high treatment burden of currently available chronic therapies for hereditary angioedema, we are pleased to receive the ILAP designation, which will enable Intellia to further accelerate the clinical development of NTLA-2002," said Intellia President and Chief Executive Officer John Leonard, M.D. "We expect to begin the Phase 2 portion of the NTLA-2002 clinical study in the first half of this year, and we look forward to working with the U.K. and other regulatory agencies to bring this investigational single-dose genome editing treatment to patients as quickly as possible."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
- ZM, NTLA, or SQ: Which Cathie Wood ARKK Stock Is Most Appealing in 2023?
- Intellia Therapeutics highlights strategic priorities, milestones for 2023
- Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
- Intellia Therapeutics to participate in a conference call with JPMorgan